MindWalk names Zachary Maben director of antigen discovery, protein engineering
HYFT•MindWalk Holdings named Zachary Maben director of antigen discovery and protein engineering as its pipeline nears preclinical efficacy studies. Joanne Lim was appointed director of preclinical development, and Shuji Sato took on oversight of the pipeline.
1. Leadership appointments
MindWalk Holdings named Zachary Maben director of antigen discovery and protein engineering. Maben joins from Arbor Biotechnologies, where he was a principal scientist, and previously held principal and senior scientist roles at Pfizer. Joanne Lim was appointed director of preclinical development, joining from Orum Therapeutics; she previously worked at Codiak Biosciences and Novartis. Shuji Sato, vice president of innovative solutions, expanded his responsibilities to include pipeline oversight.
